Study: Pfizer vaccine protects against variants of coronavirus

About 90 percent of people fully inoculated by the Pfizer-BioNTech vaccine are well protected from variants of the novel ...
Cyprus Mail on MSN

Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

Vaccine makers Pfizer PFE.N and BioNTech 22UAy.DE halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to ...
katc

Study: Protection from Pfizer, Moderna COVID-19 vaccine may last years; 'This is truly remarkable'

A recent study suggests people may have protection from the coronavirus for years if they received the Pfizer-BioNTech or Moderna vaccine. The study was published in the journal Nature. “Overall, our ...
BioSpace

Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data. Moderna is apparently also facing enrollment ...
BioPharma Dive

Pfizer, BioNTech to pause COVID vaccine study due to low enrollment

The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved COVID vaccines.

Pfizer-Backed EV-209 Trial Targets Bladder Preservation in High-Need Cancer Segment

Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Seeking Alpha

Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic ...

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit

AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record net ...